XML 63 R36.htm IDEA: XBRL DOCUMENT v3.25.4
Collaboration and license agreements (Tables)
 12 Months Ended
Dec. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Allocation of total transaction price and unsatisfied transaction price
The following table summarizes the allocation of the total transaction price to the identified performance obligations under the arrangement, and the amount of the transaction price unsatisfied as of December 31, 2025 (in thousands):
Transaction
Price
Allocated
Transaction
Price
Unsatisfied
Performance obligations:
Research and development targets$20,834 $8,049 
Option rights2,397 2,397 
Total$23,231 $10,446 
Schedule of revenue from collaboration agreements
Revenue from collaboration agreements was as follows (in thousands):
Years Ended December 31,
20252024
Revenue from collaboration agreements:
Merck KGaA Agreement$18,482 $7,304 
Merck Agreement6,020 3,979 
Betta Agreement 649 3,415 
Roche Agreement8,796 3,988 
Biogen Agreement2,000 16,898 
Total revenue from collaboration agreements$35,947 $35,584 
Schedule of financial information related to collaboration and license agreements
Supplemental information related to the collaboration and license agreements consisted of the following in the Company’s consolidated balance sheet as of December 31, 2025 (in thousands):
Accounts
Receivable
Deferred
Revenue,
Current
Deferred
Revenue,
Net of Current
Deferred
Revenue,
Total
Supplemental information:
Merck KGaA Agreement$1,892 $3,913 $— $3,913 
Betta Agreement9 531 14,194 14,725 
Roche Agreement500 8,049 1,647 9,696 
Total$2,401 $12,493 $15,841 $28,334 
Supplemental information related to the collaboration and license agreements consisted of the following in the Company’s consolidated balance sheet as of December 31, 2024 (in thousands):
Accounts
Receivable
Deferred
Revenue,
Current
Deferred
Revenue,
Net of Current
Deferred
Revenue,
Total
Supplemental information:
Merck KGaA Agreement$2,064 $5,396 $7,977 $13,373 
Merck Agreement— 3,441 2,581 6,022 
Betta Agreement1,038 4,038 11,243 15,281 
Roche Agreement— 5,837 6,656 $12,493 
Total$3,102 $18,712 $28,457 $47,169 
Schedule of supplemental financial information related to collaboration and license agreements
Supplemental financial information related to the collaboration and license agreements are (in thousands):
Years Ended December 31,
20252024
Revenue recognized that was included in the contract liability at the beginning of the period$25,930 $12,184 
Revenue recognized from performance obligations fully or partially satisfied in previous periods1,339 —